Reckitt Benckiser (RKT.L) — Company Research
Last Updated: 14 June 2026
Reckitt Benckiser Group plc (LSE: RKT) is one of the world's largest consumer health and hygiene companies, owning a portfolio of "Powerbrands" including Dettol, Lysol, Finish, Durex, Mucinex, Nurofen, Gaviscon, Strepsils and Vanish, alongside the Mead Johnson infant-nutrition business (Enfamil, Nutramigen). The 2025 financial year marked the culmination of a multi-year reshaping of the group: management completed the divestment of its Essential Home (surface and air care) business on 31 December 2025, simplified the operating model into a focused "Core Reckitt", and returned £2.3bn to shareholders. This report walks through the company's most recent reported results, segment structure, financial health, valuation and risks, drawing only on primary company filings and disclosed market data.
1. Company Snapshot
| Field | Value |
|---|---|
| Ticker / Exchange | RKT.L (London Stock Exchange) |
| Sector | Consumer Staples — Health & Hygiene |
| CEO | Kris Licht (since 1 October 2023) |
| Headquarters | Slough, United Kingdom |
| Financial year end | 31 December |
| Market cap | ~£28.6bn (June 2026) |
| Share price | ~4,491p (2 June 2026) |
| Shares outstanding | ~637.5 million |
| Employees | ~31,000 (approximate) |
| FY2025 Revenue (net) | £14,205m (+0.3% reported, +5.0% like-for-like) |
| FY2025 IFRS net profit (attributable) | £3,182m |
| FY2025 adjusted operating profit | £3,543m (margin 24.9%) |
| FY2025 full-year dividend | 212.2p per share (+5.0%) |
2. Bull & Bear Case
Bull Case
- Powerbrand portfolio with pricing power: Core Reckitt delivered +5.2% like-for-like net revenue growth in 2025, led by Dettol (now the group's largest brand by revenue), Durex, Mucinex and Finish, with price/mix driving most of the growth.
- Emerging-markets engine: Emerging Markets net revenue rose +14.6% in 2025 with broad-based, double-digit growth in China and India, giving Reckitt a structural growth lever many Western staples peers lack.
- Self-help margin story: The "Fuel for Growth" programme cut fixed costs to 19.4% of net revenue (from 20.9%) and management now targets a sub-19% fixed-cost base by end-2027, supporting reinvestment and margin expansion.
- Simpler, more focused group: The completion of the Essential Home divestment and the carve-out of Mead Johnson as "non-core" leaves a cleaner Core Reckitt business with a 4–5% medium-term LFL growth target.
- Consistent capital returns: £2.3bn was returned in 2025 (buybacks plus dividends), a 5% dividend increase was declared, and a further ~£1.6bn special dividend was paid in February 2026.
Bear Case
- Reported growth masked by FX and disposals: IFRS net revenue rose only +0.3%, with a ~£2,172m one-off gain on the Essential Home disposal flattering IFRS operating profit (+73.9%) and headline EPS.
- Mead Johnson litigation overhang: The US preterm infant-formula (NEC) litigation remains an unresolved legal and financial risk attached to the Mead Johnson nutrition business.
- European weakness: Europe net revenue fell -1.4% LFL (-3.0% IFRS) in 2025 amid a challenging consumer backdrop and softer cold & flu seasonality.
- Dilution from divestment: Management flagged a 2026 EPS headwind from the dilution created by disposing of Essential Home, with stranded costs to be absorbed.
- Currency translation: A UK-reporting, globally-earning business, Reckitt saw a -2.9% Group FX drag on net revenue in 2025, a recurring swing factor.
3. Business Segments
Reckitt now reports around three business units following the reorganisation effective 1 January 2025. The figures below are FY2025 IFRS net revenue.
| Segment | % of revenue | What it is |
|---|---|---|
| Core Reckitt (£10,234m) | 72% | The focused growth engine: Health (Mucinex, Nurofen, Strepsils, Gaviscon, Durex) and Hygiene (Dettol, Lysol, Finish, Vanish, Harpic) Powerbrands. |
| Mead Johnson Nutrition (£2,119m) | 15% | Infant and specialty nutrition (Enfamil, Nutramigen), now classified as non-core; LFL net revenue +3.8% in 2025. |
| Essential Home (£1,852m) | 13% | Surface, air and pest care brands (Air Wick, Cillit Bang, Mortein). Divested to Advent International on 31 December 2025; Reckitt retains a 30% equity interest. |
By geography, FY2025 IFRS net revenue split as Emerging Markets £4,291m (+10.5%), Europe £3,384m (-3.0%) and North America £2,559m (-3.1%).
4. How It Makes Money
How it makes money. Reckitt sells branded fast-moving consumer goods through retail and e-commerce channels worldwide. Revenue is generated from repeat purchases of everyday health and hygiene products, where brand equity, distribution scale and continual innovation (premiumisation) support pricing power and gross margins (60.8% in 2025).
Unit economics. The economic model rests on converting marketing investment (brand equity investment was 14.6% of net revenue in 2025) and R&D into market-share gains and favourable price/mix, while the "Fuel for Growth" efficiency programme reduces the fixed-cost base (to 19.4% of net revenue in 2025) to fund both reinvestment and shareholder returns.
Moat & growth mix. Reckitt's durable advantage is its portfolio of category-leading Powerbrands (such as Dettol, Lysol, Finish and Durex) with strong consumer loyalty and global distribution. Growth is weighted towards Emerging Markets, where category penetration is rising, while developed markets provide cash-generative, lower-growth franchises.
5. Financial Health
All figures below are taken from Reckitt's primary results announcements (the FY2025 results announced 5 March 2026 and prior-year releases). Reckitt reports in pounds sterling.
| Year | Revenue | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | £13,234m | — | -4.5p | 288.5p | 174.6p | — |
| FY2022 | £14,453m | +9.2% | 324.7p | 341.7p | 183.3p | — |
| FY2023 | £14,607m | +1.1% | 228.7p | 323.4p | 192.5p | — |
| FY2024 | £14,169m | -3.0% | 203.2p | 348.9p | 202.0p | £7,235m |
| FY2025 | £14,205m | +0.3% | 467.2p | 352.8p | 212.2p | £7,620m |
GAAP EPS is IFRS diluted earnings per share; Adjusted EPS is adjusted diluted earnings per share. FY2025 GAAP EPS of 467.2p was inflated by the ~£2,172m one-off gain on the Essential Home disposal; the underlying picture is better captured by adjusted diluted EPS of 352.8p (+1.1%). The long-term debt column shows total long-term borrowings at year end.
Because Reckitt reports financial results half-yearly, the table below shows the half-year split for the most recent year, most recent period first, with the full-year total in bold.
| Quarter / Half | Net revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| H2 2025 | ~£7,226m | 184.4p | — |
| H1 2025 | ~£6,979m | 168.4p | — |
| FY 2025 total | £14,205m | 352.8p | 467.2p |
Adjusted diluted EPS figures are as reported (H1 2025: 168.4p; full year: 352.8p), with the H2 figure derived by subtraction. The half-year net revenue split is derived from the interim and full-year reporting; the full-year total of £14,205m is as reported. On the balance sheet, year-end net debt fell to £6,558m (2024: £7,914m), equivalent to 1.6x adjusted EBITDA, helped by the cash proceeds from the Essential Home disposal. Free cash flow was £1,709m and cash generated from operating activities was £2,297m.
6. Valuation
Raw metrics, June 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~£28.6bn (~637.5m shares × ~4,491p) |
| Trailing P/E (GAAP) | ~9.6x (4,491p / FY2025 IFRS diluted EPS 467.2p; note: inflated by the Essential Home disposal gain — ~12.7x on adjusted diluted EPS of 352.8p) |
| P/E (forward) | ~12.6x (4,491p / ~355p estimated FY2026 adjusted diluted EPS, reflecting broadly flat EPS guidance with disposal dilution) |
| P/S (TTM) | ~2.0x (market cap ~£28.6bn / FY2025 net revenue £14,205m) |
| EV/EBITDA (TTM) | ~8.7x (EV ~£35.1bn / adjusted EBITDA ~£4.05bn; EBITDA = adjusted operating profit £3,543m + D&A ~£499m. IFRS EBITDA is distorted by the £2,172m disposal gain, so the adjusted figure is used) |
| P/FCF | ~16.7x (market cap ~£28.6bn / free cash flow £1,709m per FY2025 cash flow statement) |
| Enterprise value | ~£35.1bn (market cap ~£28.6bn + total borrowings £8,430m − cash £1,952m per FY2025 balance sheet) |
| 52-week high | 6,514p |
| 52-week low | 4,465p |
| Short interest (% of float) | ~0.5% (aggregate FCA-disclosed short positions around the 0.5% disclosure threshold) |
| Days to cover | — not published for this period (short interest is low) |
7. Capital Structure & Returns
Reckitt funds itself largely through bonds, with total borrowings of £8,430m at 31 December 2025 (of which £7,620m is long-term) against cash and cash equivalents of £1,952m, leaving net debt of £6,558m (1.6x adjusted EBITDA). The group returned £2.3bn to shareholders in 2025: approximately £0.9bn via share buybacks and the remainder through ordinary dividends, with the full-year dividend rising 5% to 212.2p. A further ~£1.6bn special dividend — the excess capital from the Essential Home divestment — was paid in February 2026, and management has indicated the next buyback tranche would commence in 2026.
8. Peer Comparison
| Peer | Market cap (June 2026) | Key 2025 metric |
|---|---|---|
| Unilever (LSE: ULVR) | ~£110bn | FY2025 turnover ~€60bn; underlying sales growth mid-single digit |
| Procter & Gamble (NYSE: PG) | ~$360bn | FY2025 net sales ~$84bn; organic sales growth low-single digit |
| Colgate-Palmolive (NYSE: CL) | ~$73bn | FY2025 net sales ~$20bn; organic sales growth mid-single digit |
| Haleon (LSE: HLN) | ~£37bn | FY2025 revenue ~£11bn; consumer-health pure-play, organic growth mid-single digit |
Peer market caps and metrics are approximate and drawn from each company's most recent disclosures; they are provided for scale and context only.
9. Insider & Institutional Activity
The most recent disclosed director dealings show Chair Jeremy Darroch and a non-executive director adding to their holdings via on-market purchases. Reckitt's CEO is Kris Licht.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Jeremy Darroch (Chair) | 29 May 2026 | Purchase | 2,132 | ~£46.87 | ~£99,927 | On-market |
| Tamara Ingram (Non-Exec Director) | 29 May 2026 | Purchase | 364 | ~£46.87 | ~£17,061 | On-market |
Separately, the company continued its own share buyback, purchasing 192,000 shares on 29 May 2026 at a volume-weighted average price of 4,660.56p, held in treasury.
10. Key Risks
- Litigation (Mead Johnson / NEC): Ongoing US litigation relating to Mead Johnson's preterm infant formula (necrotising enterocolitis claims) is an unresolved legal and potential financial exposure.
- Foreign-exchange translation: As a sterling reporter with global earnings, currency swings (-2.9% Group FX drag in 2025) can materially affect reported revenue and EPS.
- Consumer / macro: A weak European consumer and variable cold & flu seasonality pressure volumes in developed markets.
- Execution & stranded costs: Absorbing stranded costs and managing dilution following the Essential Home divestment is a 2026 execution risk.
- Competition & private label: Intense competition from global peers and retailer own-label can erode share and pricing in mature categories.
11. Recent Developments
- 29 May 2026 — Director purchases and continued buyback. Chair Jeremy Darroch and NED Tamara Ingram bought shares on-market; Reckitt repurchased a further 192,000 shares into treasury.
- 05 Mar 2026 — FY2025 results. Net revenue £14,205m (+0.3% reported, +5.0% LFL), Core Reckitt LFL +5.2%, adjusted operating profit +5.3% (constant FX), full-year dividend raised 5% to 212.2p.
- 28 Feb 2026 — Special dividend. Approximately £1.6bn special dividend, representing excess capital from the Essential Home divestment, paid to shareholders.
- 31 Dec 2025 — Essential Home divestment completed. Sold to Advent International for net consideration of £2,172m; Reckitt retains a 30% equity interest in the acquisition vehicle.
12. Key Dates
- 29 Jul 2026 — H1 2026 interim results (expected)
- 21 Aug 2026 — 2026 interim dividend payment (expected)
- 16 Oct 2026 — Q3 2026 trading statement (expected)
- 04 Mar 2027 — FY2026 full-year results (expected)
For live pricing and charts, see ChartsView's Live Charts, track scheduled catalysts on the Economic Calendar, and discuss this company in the Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Loading research report…
13. Thesis Verdict
The central thesis. Reckitt is a global consumer health and hygiene group that earns money from repeat purchases of branded everyday products (Dettol, Lysol, Finish, Durex, Mucinex), supported by a 60.8% gross margin and pricing power. In FY2025 it grew like-for-like net revenue +5.0% (Core Reckitt +5.2%) to £14,205m and adjusted operating profit +5.3%, lifting the dividend 5% to 212.2p, while completing the divestment of Essential Home and returning £2.3bn to shareholders. The primary structural driver is Emerging Markets, where net revenue rose +14.6%.
What would confirm or break it. Continued mid-single-digit Core Reckitt like-for-like growth with margin expansion from the Fuel for Growth programme would confirm the thesis. A material adverse development in the Mead Johnson (NEC) litigation, a sustained currency or European-consumer drag, or any change to the stated capital-return and growth profile would call it into question.
Watchpoints
- ConfirmsH1 2026 interim results (45 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Powerbrand portfolio with pricing power:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "Litigation (Mead Johnson / NEC):" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 14 Jun 2026.